In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.
Are you the creator of this podcast?
and pick the featured episodes for your show.
Connect with listeners
Podcasters use the RadioPublic listener relationship platform to build lasting connections with fansYes, let's begin connecting
Find new listeners
Understand your audience
Engage your fanbase